Summary Topoisomerase II is a key target for many anti-cancer drugs used to treat breast cancer. In human cells there are two closely related, but differentially expressed, topoisomerase II isoforms, designated topoisomerase Ila and P. Here, we report the production of a new polyclonal antibody raised against a fragment of the C-terminal domain of the 180 kDa form of topoisomerase II (the P isoform), which does not cross-react with the 170 kDa form (the a isoform). Using this antibody, together with a polyclonal antibody specific for the 170 al., 1991; Capranico and Zunino, 1992; Pommier, 1993) . DNA topoisomerase II is a nuclear enzyme which alters DNA tertiary structure through transient double-stranded breakage of the DNA backbone and subsequent passage of a second intact DNA duplex through the break (reviewed in Osheroff et al., 1991; Wang, 1985; Austin and Fisher, 1990; Watt and Hickson, 1994) . The aforementioned drugs, as well as several other intercalating agents, including amsacrine (Nelson et al., 1984) , trap the enzyme in a covalently bound reversible complex with DNA, termed the cleavable complex. The stabilisation of this complex prevents religation of the broken DNA and produces lesions which are thought to be cytotoxic by virtue of their ability to inhibit the passage of the replication fork. There is evidence that the cellular level of topoisomerase II determines the extent of cleavable complex formation after drug treatment and, therefore, the degree of drug toxicity. Low levels of topoisomerase II are associated with the induction of a reduced number of DNA lesions and hence increased drug resistance (Beck et al., 1993; Pommier, 1993) . The converse relationship has been shown in mutant cell lines hypersensitive to topoisomerase II inhibitors (Davies et al., 1988) and also in testicular teratoma cell lines compared with bladder cell lines (Fry et al., 1991) .
Topoisomerase II is a key target for many anti-cancer drugs used to treat cancer, including doxorubicin, epirubicin, mitoxantrone and etoposide (reviewed in Liu, 1989; Osheroff et al., 1991; Capranico and Zunino, 1992; Pommier, 1993) . DNA topoisomerase II is a nuclear enzyme which alters DNA tertiary structure through transient double-stranded breakage of the DNA backbone and subsequent passage of a second intact DNA duplex through the break (reviewed in Osheroff et al., 1991; Wang, 1985; Austin and Fisher, 1990; Watt and Hickson, 1994) . The aforementioned drugs, as well as several other intercalating agents, including amsacrine (Nelson et al., 1984) , trap the enzyme in a covalently bound reversible complex with DNA, termed the cleavable complex. The stabilisation of this complex prevents religation of the broken DNA and produces lesions which are thought to be cytotoxic by virtue of their ability to inhibit the passage of the replication fork. There is evidence that the cellular level of topoisomerase II determines the extent of cleavable complex formation after drug treatment and, therefore, the degree of drug toxicity. Low levels of topoisomerase II are associated with the induction of a reduced number of DNA lesions and hence increased drug resistance (Beck et al., 1993; Pommier, 1993) . The converse relationship has been shown in mutant cell lines hypersensitive to topoisomerase II inhibitors (Davies et al., 1988) and also in testicular teratoma cell lines compared with bladder cell lines (Fry et al., 1991) .
There are two isoforms of topoisomerase II in mammalian cells that are products of different genes (Drake et al., 1989; Jenkins et al., 1992; Tan et al., 1992; Austin et al., 1993) .
These isoforms are termed a (170 kDa form) and , ((180 kDa form) and have different patterns of expression, suggesting that they might perform different functions. The a isoform is produced primarily in late S-phase and during the G2/M phase of the cell cycle (Woessner et al., 1991) , and is apparently more sensitive to teniposide and merbarone than is the Correspondence: ID Hickson *Present address: Department of Medicine, Nottingham City Hospital, Nottingham NG5 IPB, UK Received 7 April 1995; revised 10 July 1995; accepted 14 July 1995 P isoform, at least in vitro (Drake, et al., 1989) . The gene encoding the a isoform has been mapped to chromosome 17q21-22 in humans (Tsai-Pflugfelder et al., 1988) . The P isoform is expressed throughout the cell cycle, with higher levels seen in non-proliferating cells (Woessner et al., 1991) and is encoded on chromosome 3p24 in humans (Jenkins et al., 1992; Tan et al., 1992) .
Drug resistance is a major clinical problem in the treatment of solid tumours. Tumours often become resistant to multiple, structurally unrelated drugs as a result of expression of the membrane efflux pump, P-glycoprotein (reviewed in Bradley and Ling, 1994) . This is the classical form of multidrug resistance (MDR). However, atypical MDR, due to altered topoisomerase II activity, has also been well documented (Beck et al., 1987; Morrow and Cowan, 1990; Patel and Fisher, 1993; reviewed in Beck, et al., 1993) . It is possible that tumour levels of topoisomerase II could strongly influence whether a particular drug will be effective in the treatment of that tumour. (Smith and Makinson, 1989; Wells et al., 1994) .
Whole cell extraction of topoisomerase II Whole cell extracts were made using the method of Drake et al. (1989) . Briefly, cells were trypsinised, washed in PBS containing 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 mM benzamidine, 10 g ml-' soybean trypsin inhibitor and 50 lg ml-' leupeptin and then lysed in 1 ml of 2% sodium dodecyl sulphate (SDS) (Figure 1 ). This C- Sensitivity to mitoxantrone is related to expression of both isoforms. There was no correlation between topoisomerase II protein levels and sensitivity to the alkylating agent chlorambucil, suggesting that these cell lines do not have a common mechanism underlying drug sensitivity that could explain the relative sensitivity to topoisomerase II inhibitors. Our study has also shown that the two isoforms are apparently not co-ordinately expressed in breast cancer cell lines. We have described the production of a new antibody that specifically detects the 180 kDa topoisomerase I1p isoform.
This may prove useful in the assessment of topoisomerase I,B expression in primary cancers. A number of anti-topoisomerase II antibodies have been described previously; however, many of these recognise either the a isoform alone or both isoforms. In our study, where the two isoforms have clearly been distinguished, the results indicate that both isozymes are potential drug targets for at least some classes of topoisomerase II inhibitor. We would suggest, therefore, that the potential for each enzyme to act as a target for a particular drug needs to be analysed separately.
There have been previous studies in which panels of cell lines from a single tumour type have been analysed. For example, in a panel of lung cancer cell lines, it was found that topoisomerase II activity (presumably representing the combined activity of the two topoisomerase II isoforms) correlated with sensitivity to topoisomerase II inhibitors (Kasahara et al., 1992) . A similar conclusion was drawn by Giaccone et al. (1992) , using a different panel of lung cancer cell lines. In a previous study, we showed that three cell lines from testicular teratomas, which are well known to be highly sensitive in vivo and in vitro to topoisomerase II inhibitors, had higher topoisomerase II levels than cell lines derived from bladder tumours, which are known to be only moderately drug sensitive (Fry et al., 1991 Pommier, 1993; Beck et al., 1993) . However, only in a limited number of studies has the relationship between intrinsic drug sensitivity and topoisomerase II expression levels been analysed. The six cells lines used in our study had not previously been exposed to anti-cancer drugs in vitro and were derived from different genetic backgrounds.
Our data are in agreement with those of Brown et al. (1995) in showing that etoposide sensitivity appears to correlate more closely with expression of the isoform than of the a isoform. Moreover, although mitoxantrone sensitivity correlated with expression of both topoisomerase II isoforms, the observation that there is a relationship between topoisomerase Ip expression and mitoxantrone sensitivity is compatible with the finding that topoisomerase IIP expression is reduced in mitoxantrone-resistant derivatives of HL60 cells (Harker et al., 1991) . These data suggest that mitoxantrone may have some selectivity for topoisomerase Ilp, at least in cell line models. Thus, the P isoform may be an important target (or indeed the primary target) for two of the most widely used classes of topoisomerase II inhibitors.
Sensitivity to doxorubicin showed no correlation with expression of either of the topoisomerase II isoforms, yet this commonly used drug is known to be a topoisomerase II inhibitor . However, doxorubicin-induced toxicity may be mediated via several other mechanisms, including generation of free radicals, lipid peroxidation and interactions with iron (Bachur et al., 1979; Tritton, 1991) . These non-topoisomerase II-dependent mechanisms may be important for toxicity in the drug concentration range used in this study. Indeed, high drug concentrations have been found previously to be required to detect protein-associated lesions (i.e. cleavable complex), compared with other topoisomerase II-targeting drugs (Zwelling et al., 1993) . Topoisomerase IIP has been reported not to be differentially regulated as cells traverse the cell cycle (Woessner et al., 1991) , although there is recent evidence from studies in proliferating lymphocytes that this isoform is up-regulated during commitment to proliferation (Kaufmann et al., 1994) . Because the isoform is expressed in a wide range of cell types in vivo (unlike the a isoform; Sandri et al. a manuscript in preparation), irrespective of their proliferation status, it is not unreasonable to assume that topoisomerase II3 forms a significant target for anti-cancer drug therapy (particularly with the epipodophyllotoxins and mitoxantrone) in breast cancer patients.
Our study analysed the relationship between mRNA and protein expression for topoisomerase hIa and P. Our results contrast with those for cell lines with acquired drug resistance in vitro, which have shown that down-regulation of topoisomerase Ila and P mRNA parallels protein downregulation in many cases (reviewed in Morrow and Cowan, 1990; Giaccone, et al., 1992; Beck et al., 1993) . In the cell lines studied here, which have not been exposed previously to cytotoxic drugs, there was no correlation between levels of mRNA and protein for either topoisomerase II isoform, in agreement with the conclusions of Peters et al. (1994) . Thus, the relationship between mRNA level and protein expression differed for each cell line, which suggests that posttranslational mechanisms may also be important in the regulation of topoisomerase II protein levels. Our data also indicate that attempts to quantify expression of topoisomerase II mRNAs by PCR in human tumours might not form a useful guide in the selection of patients for therapy, since mRNA levels are unlikely to reflect levels of the corresponding protein. Our study suggests that the level of expression of the a and f isoforms influences sensitivity to different classes of topoisomerase II-targeting drugs. A more definitive demonstration of this relationship will probably be forthcoming only when the level of expression of the individual isozymes is manipulated in human cells using antisense or overexpression constructs. It will now be important to assess expression of these isoforms in primary tumours, as it may be possible in the future to select particular drugs for use in therapy based upon topoisomerase II isoform expression in individual tumours. Thus, attempts to select drugs for treatment of individual patients rationally may improve their clinical response.
